APLLTDNSEALEMBIC PHARMA LTD· Pharmaceuticals & BiotechnologyHighNegative
Announced Mon, 10 Aug, 2026 · 19:07 IST

Company Secretary Manisha Saraf resigns from Alembic Pharmaceuticals

Kmp ResignedManagement Changes View source PDFExplain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.6%Reaction day
₹834.00
prior close
₹831.35
announcement price
After-mkt
timing
Nifty Microcap 250market-0.2%+0.8% vs market
Pharmaceuticals peers, median of 164sector+0.1%+0.6% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
-0.3
15m
-0.4
30m
-0.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.6-0.2+0.8+0.1+0.6
Next day
+1.2+0.2+1.0-0.5+1.7
2d
-0.4+0.4-0.7+0.1-0.5
3d
-1.1+0.4-1.5-0.4-0.7
4d
-1.2+0.6-1.8-0.9-0.3
5d
-0.9+0.9-1.8-0.5-0.4
1w
-2.3+0.9-3.1-1.0-1.3
15d
+1.2+0.9+0.3-0.8+2.0
1m
-3.2+2.3-5.6+1.1-4.4
2m
-5.3-1.1-4.2-3.1-2.2
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharmaceuticals informed the stock exchanges that Ms. Manisha Saraf, Company Secretary and Compliance Officer (Key Managerial Personnel), has resigned effective close of business hours on 10th August 2026. In her resignation letter dated 4th June 2026, she stated she is leaving to pursue a new opportunity better aligned with her long-term career aspirations.

Likely market impact

Company Secretary is a key compliance role; investors should watch for timely appointment of a replacement to avoid any disclosure or compliance gaps.